TDMS Study 05704-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
RESORCINOL
NTP Experiment-Test: 05704-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/18/94
Route: GAVAGE Time: 17:58:56
Facility: International Research and Development Corp.
Chemical CAS #: 108-46-3
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05704-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RESORCINOL Date: 09/18/94
Route: GAVAGE Time: 17:58:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 112MG/KG 225MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 17 15 16
Dead 5 10 21
Accident 4
Survivors
Terminal Sacrifice 28 25 9
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50)
Intestine Large, Cecum (47) (46) (44)
Intestine Large, Colon (47) (47) (46)
Schwannoma Malignant, Metastatic, Epididymis 1 (2%)
Intestine Large, Rectum (47) (49) (47)
Intestine Small, Duodenum (47) (47) (44)
Leiomyosarcoma 1 (2%)
Intestine Small, Ileum (46) (47) (43)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Intestine Small, Jejunum (46) (47) (44)
Liver (50) (50) (50)
Hepatocellular Adenoma 1 (2%)
Histiocytic Sarcoma, Metastatic 1 (2%)
Neoplastic Nodule 1 (2%)
Mesentery (3) (5) (1)
Lipoma 1 (20%)
Schwannoma Malignant, Metastatic, Epididymis 1 (20%)
Pancreas (49) (50) (50)
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
Schwannoma Malignant, Metastatic, Epididymis 1 (2%)
Salivary Glands (50) (50) (50)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Schwannoma Malignant 1 (2%)
Stomach, Forestomach (49) (50) (50)
Stomach, Glandular (49) (50) (49)
Schwannoma Malignant, Metastatic, Epididymis 1 (2%)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
Tooth (1) (1)
Page 2
NTP Experiment-Test: 05704-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RESORCINOL Date: 09/18/94
Route: GAVAGE Time: 17:58:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 112MG/KG 225MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (50) (49)
Adenoma 1 (2%)
Schwannoma Malignant, Metastatic, Epididymis 1 (2%)
Adrenal Gland, Medulla (49) (50) (49)
Pheochromocytoma Malignant 5 (10%) 2 (4%)
Pheochromocytoma Benign 9 (18%) 8 (16%) 5 (10%)
Pheochromocytoma Benign, Multiple 1 (2%)
Islets, Pancreatic (49) (49) (50)
Adenoma 2 (4%) 2 (4%)
Pituitary Gland (50) (50) (49)
Pars Distalis, Adenoma 14 (28%) 9 (18%) 3 (6%)
Thyroid Gland (49) (49) (49)
C-Cell, Adenoma 3 (6%) 4 (8%) 5 (10%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50)
Schwannoma Malignant 1 (2%)
Preputial Gland (50) (49) (50)
Adenocarcinoma 1 (2%)
Adenoma 8 (16%) 4 (8%) 2 (4%)
Adenoma, Multiple 2 (4%)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Prostate (50) (50) (49)
Testes (50) (50) (50)
Schwannoma Malignant, Metastatic, Epididymis 1 (2%)
Interstitial Cell, Adenoma 8 (16%) 7 (14%) 3 (6%)
Interstitial Cell, Adenoma, Multiple 37 (74%) 37 (74%) 28 (56%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05704-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RESORCINOL Date: 09/18/94
Route: GAVAGE Time: 17:58:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 112MG/KG 225MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Lymph Node (50) (50) (50)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Lymph Node, Mesenteric (50) (50) (49)
Schwannoma Malignant, Metastatic, Epididymis 1 (2%)
Spleen (50) (50) (49)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Thymus (46) (46) (48)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (50) (49)
Adenocarcinoma 1 (2%)
Fibroadenoma 2 (4%) 1 (2%)
Skin (50) (50) (50)
Epidermis, Keratoacanthoma 1 (2%) 2 (4%) 1 (2%)
Epidermis, Squamous Cell Papilloma 2 (4%)
Epidermis, Trichoepithelioma 1 (2%)
Subcutaneous Tissue, Fibroma 3 (6%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3) (1)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Astrocytoma Malignant 1 (2%) 1 (2%)
Glioma NOS 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Chordoma, Metastatic, Uncertain Primary Site 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Page 4
NTP Experiment-Test: 05704-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RESORCINOL Date: 09/18/94
Route: GAVAGE Time: 17:58:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 112MG/KG 225MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Nose (49) (49) (50)
Trachea (50) (50) (49)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Pinna, Schwannoma Malignant 1 (100%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Schwannoma Malignant, Metastatic, Epididymis 1 (2%)
Cortex, Adenoma 1 (2%)
Pelvis, Transitional Epithelium, Papilloma 1 (2%) 1 (2%)
Urinary Bladder (50) (50) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia Mononuclear 17 (34%) 25 (50%) 8 (16%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
Mesothelioma Malignant 4 (8%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05704-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC RESORCINOL Date: 09/18/94
Route: GAVAGE Time: 17:58:56
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 112MG/KG 225MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 49 31
Total Primary Neoplasms 124 120 64
Total Animals with Benign Neoplasms 46 48 31
Total Benign Neoplasms 90 84 51
Total Animals with Malignant Neoplasms 27 32 12
Total Malignant Neoplasms 33 36 13
Total Animals with Metastatic Neoplasms 4 1 1
Total Metastatic Neoplasm 15 8 1
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 34817-34817/34817
--multipart-boundary--